Company news

BioMarin Pharmaceutical Inc. news in 2023

BioMarin Pharmaceutical Inc.'s news releases, calls and decks from 2023, newest first.

View company

BioMarin Announces Governance Enhancements and Value Creation Initiatives

December 19, 2023

BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany

November 27, 2023

BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year

October 31, 2023

BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer

October 31, 2023

U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia

October 19, 2023

BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4: 30pm ET

October 16, 2023

BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting

September 20, 2023

BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia

September 14, 2023

BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York

September 10, 2023

BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th

September 5, 2023

BioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe

August 29, 2023

BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date

July 30, 2023

BioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4: 30pm ET

July 11, 2023

U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A

June 28, 2023

BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress

June 21, 2023

BioMarin to Participate in Bank of America 2023 Health Care Conference

May 3, 2023

BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues

April 25, 2023

BioMarin to Host First Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, April 26, at 4: 30pm ET

April 12, 2023

BioMarin to Share Updated Data at 2023 American College of Medical Genetics and Genomics (ACMG) Meeting Demonstrating Commitment to Understanding Long-Term Benefit of VOXZOGO® in Children with Achondroplasia

March 13, 2023

FDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO® (vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 5

March 6, 2023

BioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A

March 5, 2023

BioMarin to Participate in Three Investor Conferences in March

March 1, 2023

BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business

February 26, 2023

BioMarin to Participate Virtually at SVB Securities Global Biopharma Conference on February 16, 2023

February 13, 2023

BioMarin to Host Fourth Quarter and Full-Year 2022 Financial Results Conference Call and Webcast on Monday, February 27, at 4: 30 p.m. ET

February 6, 2023

BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™ in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at 3-Year Analysis

January 7, 2023

BioMarin to Present at 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, at 10: 30 am PT /1: 30 pm ET, in San Francisco, CA

January 3, 2023

European Medicines Agency Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2

January 2, 2023

Calls in 2023

Decks in 2023